Employees |
8. Employees
Schedule
of number of employees
|
|
Year ended December 31,
|
|
|
Year ended December 31,
|
|
|
Year ended December 31,
|
|
|
|
2022 Number
|
|
|
2021 Number
|
|
|
2020 Number
|
|
Number of employees |
|
|
|
|
|
|
|
|
|
Average monthly number or persons (including directors) employed by the Group: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
70 |
|
|
|
61 |
|
|
|
66 |
|
Management, administration and operations |
|
|
9 |
|
|
|
8 |
|
|
|
13 |
|
Number
of employees |
|
|
79 |
|
|
|
69 |
|
|
|
79 |
|
TC
BIOPHARM (HOLDINGS) PLC
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
8. Employees (continued)
Management
includes employees who are involved in both research and development and administrative operations.
Schedule
of staffing costs
|
|
Year ended December 31,
|
|
|
Year ended December 31,
|
|
|
Year ended December 31,
|
|
|
|
2022 |
|
|
2021 |
|
|
2020 |
|
|
|
£ |
|
|
£ |
|
|
£ |
|
Staff costs – included in research and development |
|
|
|
|
|
|
|
|
|
|
|
|
Wages and salaries |
|
|
3,512,525 |
|
|
|
2,989,066 |
|
|
|
3,443,726 |
|
Social security costs |
|
|
432,388 |
|
|
|
313,138 |
|
|
|
386,063 |
|
Pension costs – defined contribution |
|
|
156,360 |
|
|
|
94,938 |
|
|
|
130,339 |
|
Share based payments |
|
|
403,803 |
|
|
|
- |
|
|
|
316,259 |
|
Total staff costs |
|
|
4,505,076 |
|
|
|
3,397,142 |
|
|
|
4,276,387 |
|
Staff costs – included in administrative expenses |
|
|
|
|
|
|
|
|
|
|
|
|
Wages and salaries |
|
|
1,586,591 |
|
|
|
877,752 |
|
|
|
703,366 |
|
Social security costs |
|
|
249,091 |
|
|
|
56,646 |
|
|
|
99,040 |
|
Pension costs – defined contribution |
|
|
59,801 |
|
|
|
42,034 |
|
|
|
24,548 |
|
Share based payments |
|
|
719,447 |
|
|
|
- |
|
|
|
256,803 |
|
Total staff costs |
|
|
2,614,930 |
|
|
|
976,432 |
|
|
|
1,083,757 |
|
Staff costs – combined |
|
|
|
|
|
|
|
|
|
|
|
|
Wages and salaries |
|
|
5,099,116 |
|
|
|
3,866,818 |
|
|
|
4,147,091 |
|
Social security costs |
|
|
681,479 |
|
|
|
369,784 |
|
|
|
485,102 |
|
Pension costs – defined contribution |
|
|
216,161 |
|
|
|
136,972 |
|
|
|
154,887 |
|
Share based payments |
|
|
1,123,250 |
|
|
|
- |
|
|
|
573,062 |
|
Total staff costs |
|
|
7,120,006 |
|
|
|
4,373,574 |
|
|
|
5,360,142 |
|
Schedule
of directors remuneration
Directors’ remuneration |
|
Year ended December 31,
|
|
|
Year ended December 31, |
|
|
Year ended December 31,
|
|
|
|
2022 |
|
|
2021 |
|
|
2020 |
|
|
|
£ |
|
|
£ |
|
|
£ |
|
Directors’ remuneration in respect of qualifying services |
|
|
1,203,537 |
|
|
|
1,046,324 |
|
|
|
967,651 |
|
Directors’ employer’s pension contributions |
|
|
72,176 |
|
|
|
15,001 |
|
|
|
14,376 |
|
Directors remuneration |
|
|
1,275,713 |
|
|
|
1,061,325 |
|
|
|
982,027 |
|
The
total remuneration of the highest paid or receivable by the highest paid director in the year ended December 31, 2022 was £443,817
(2021: £332,468
and 2020: £365,194).
The Group pension contributions in respect of the highest paid director totaled £Nil
for the year to December 31, 2022 (2021: £Nil
and 2020: £Nil).
The highest paid director did not exercise any share options in the period. No other directors exercised share options in the period.
TC
BIOPHARM (HOLDINGS) PLC
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
|